MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Funding Opportunities: Pioneers, Architects & Consolidators
Funding: U.S. Federal
*Funding: HHS
*HHS: Contracts, Contractors & Awards
*BARDA: Contracts (IDIQ, GWACS, Etc.), Contractors & Awardees
*Contractors & Awardees: BARDA
MediWound Ltd. (NASDAQ: MDWD)
Organization & Developments: MediWound
Parents
MediWound Ltd. (NASDAQ: MDWD)
Children
*Focused on developing, manufacturing and commercializing novel therapeutics based on its patented proteolytic enzyme technology to address unmet needs in the fields of severe burns, chronic and other hard-to-heal wounds
*MediWound is a fully integrated biopharmaceutical company
*NexoBrid
*PolyHeal
2017: Mediwound_5 Top-Rated Biotech Stocks with Big Upside Potential_tipranks
2018: HHS Enlists MediWound to Develop Treatment for Sulfur Mustard Injury
2019: Vericel Enters into Exclusive License Agreement with MediWound for North American Rights to NexoBrid, a Biological Orphan Product for Debridement of Severe Thermal Burns
2020: MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid to BARDA for Emergency Response Preparedness
2020: MediWound: A Collectable Investment Worthy Of A Long-Term Hold
2020: MediWound: An Underfollowed Opportunity At A Discount
2021: FDA Strikes Off MediWound - Vericel's NexoBrid Biologics License Application; Stocks Drop
2021: MediWound: Managing A Position Ahead Of NexoBrid's PDUFA
2021: UPDATE 1-FDA declines to approve MediWound treatment for burns
2023: MediWound: Gaining Traction_ seekingalpha.com
2024: MediWound Ltd. 2023 Q4 - Results - Earnings Call Presentation
2025: MediWound Ltd.: Undervalued High-Growth Potential
Jumps
*Key People: MediWound
Finance & Acquisitions: MediWound